EUCTR2011-003625-97-GR进行中（未招募）1 期
Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes
Hellenic Cooperative Oncology Group0 个研究点开始时间: 2012年8月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Written informed consent
- •Female patients aged 18 to 75 years
- •Patients must have received 1st-line chemotherapy for locally recurrent / metastatic disease
- •Prior taxane-containing treatment (paclitaxel, docetaxel or nab-paclitaxel), either for advanced disease or as neoadjuvant / adjuvant chemotherapy. In case of early relapse (relapse during neoadjuvant / adjuvant chemotherapy or disease-free interval less than 6 months), neoadjuvant / adjuvant chemotherapy will be considered as 1st-line treatment
- •Diagnosis of HER-2 negative (HER-2 <2+ by immunohistochemistry and/or FISH or CISH negative) metastatic breast adenocarcinoma confirmed by the pathology department of the enrolling institution
- •Eastern Cooperative Oncology Group performance status (PS) of 0-1
- •Life expectancy of at least 12 weeks
- •Measurable disease by the Response Criteria in Solid Tumors 1.1 (RECIST 1.1) method (at least one measurable lesion) [16]
- •Laboratory values within the specified ranges within 1 week of study enrolment:
- •oHemoglobin = 9.0 g/dL
- •oAbsolute neutrophil count of = 1.5 x 109/L
- •oThrombocyte count of = 100 x 109/L
- •oSerum creatinine = 1.5 upper limit of normal (ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded [17]
- •Web link to be used to estimate glomerular filtration rate (GFR) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula http://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr
- •SGOT (AST), SGPT (ALT) = 2.5 x ULN and alkaline phosphatase = 2.5 x ULN, total bilirubin = ULN (the same limits also refer to patients with liver metastases)
- •Previous treatment for loco-regional disease is allowed, including surgical procedures or palliative radiotherapy (such treatments must have been completed at least 4 weeks before enrolment)
- •Compliance of the patient regarding scheduled visits, treatment plan, laboratory tests and other procedures of the study.
- •The enrolment of patients with controlled brain metastases is allowed (metastases that have been treated with radiotherapy and remained stable for at least 4 weeks following the completion of radiation treatment)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •Patients that have received more than one lines of chemotherapy for locally recurrent / metastatic disease
- •Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a wash-out period of two weeks is necessary for patients who are already on these treatments) (Appendix A and B)
- •Patients with CTC grade 2 or greater neuropathy at baseline
- •Diagnosis of spinal cord compression or carcinomatous meningitis
- •Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
- •Patients with clinically significant cardiac disease (e.g. congestive heart failure, unstable angina, myocardial infarction) within 6 months from study entry
- •Any other significant acute or chronic medical or psychiatric condition or abnormal laboratory finding which, according to the investigator’s opinion, could result in excessive danger, regarding the participation of the patient in the study.
- •Psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocol
- •Any concurrent active malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix
- •Concurrent administration of other investigational treatments and/or anti-neoplastic agents
- •Pregnancy or lactation. Patients should be surgically sterile or post-menopausal or they must agree to use adequate contraceptive methods during study period. For all patients of childbearing potential a serum or urine pregnancy test is needed. The definition of effective contraceptive methods will be based on the investigator’s opinion.
- •History of severe hypersensitivity reaction (=grade 3) to docetaxel or polysorbate 80 containing drugs
研究者
相似试验
已完成
2 期
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With TaxanesBreast CancerNCT01693549Hellenic Cooperative Oncology Group84
进行中（未招募）
1 期
A randomised study of cabazitaxel versus vinflunine in bladder carcinoma.metastatic or locally advanced transitional cell carcinoma of the urotheliumMedDRA version: 14.1Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10005084Term: Bladder transitional cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002826-55-ESAssociació Per a la Recerca Oncològica (APRO)70
招募中
不适用
A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urotheliumUrothelial Cancer1003836410046400Bladder CancerNL-OMON38902Associació Per a la Recerca Oncològica (APRO)50
进行中（未招募）
不适用
A randomised study of cabazitaxel versus vinflunine in bladder carcinoma.metastatic or locally advanced transitional cell carcinoma of the urotheliumMedDRA version: 17.1Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10005084Term: Bladder transitional cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002826-55-NLAssociació Per a la Recerca Oncològica (APRO)372
进行中（未招募）
不适用
2nd line treatment with cabazitaxel in patients with NSCLCPatients with stage IIIB with pleural effusion or stage IV NSCLC with documented disease progression during or after completion of docetaxel-based treatment are eligible for the study.EUCTR2012-000275-16-GRHellenic Oncology Research Group (H.O.R.G.)